BioCentury
ARTICLE | Financial News

On heels of series C, Harpoon files for IPO

January 4, 2019 10:03 PM UTC

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ.

Harpoon is developing tri-specific T cell activating constructs (TriTACs), which are next-generation three-pronged antibody-like constructs that could outdo their predecessors via better serum half-life and a tissue-penetration that reaches into solid tumors (see "Bispecific Redirection")...